NeoStem, ATMI in Technology Platform Pact

NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy, LLC, have entered a collaboration with ATMI, Inc., on a non-exclusive basis, to enable PCT and its affiliates to offer clients access to ATMI’s Integrity Xpansion technology platform. The Xpansion system will provide bioreactor expansion capability to help clients create and customize an appropriate development program to suit their needs.
 
The Xpansion system is part of ATMI’s LifeSciences Integrity family of single-use technologies and has been developed for large-scale production of stem cells. It’s based on stacked plates made from the same plastic material as multiple-tray stack systems.
 
“PCT is pleased to be working with ATMI to offer our clients and potential clients the Xpansion system technology that we believe to be the next generation of two-dimensional technology for adherent cell culture, including stem cells,” said Robert A. Preti, Ph.D., president of PCT and chief scientific officer of NeoStem. “Along with our investments in engineering and innovation, the Xpansion system is an exciting tool that has the potential to help a valuable segment of our client base develop cellular therapeutics in a more cost effective and robust way.”
 
“This collaboration is mutually beneficial to both PCT and ATMI, as we each have specialized knowledge in our respective spheres of expertise that will ultimately benefit our clients and this emerging industry,” said senior vice president and general manager of ATMI LifeSciences, Mario Philips. “Our collaboration will allow us to share resources and information, and take advantage of new opportunities for business development to the benefit of our customers.”